Baxalta Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Takeda Pharmaceutical Company Limited

Baxter Aktiengesellschaft

Stichting Sanquin Bloedvoorziening

Nektar Therapeutics

Immuno Aktiengesellschaft

Baxter Innovations Gmbh

Children's Medical Center Corporation

Dyax Corporation

Baxler Innovations Gmbh

Baxter Health S.a.

The Cbr Institute for Biomedical Research, Inc.

Friedrich Dorner

Friedrich Scheiflinger

Michael Dockal

Peter Turecek

Randolf Kerschbaumer

Thomas Polakowski

Rudolf Hartmann

Hans-Peter Schwarz

Hartmut Ehrlich

Ulrich Reineke

Frank Osterkamp

Juergen Siekmann

Gerhard Antoine

Hanspeter Rottensteiner

Miha Furlan

Klaus Zimmermann

Franziska Horling

Bernhard Laemmle

Luigina Tagliavacca

Johannes Lengler

Barbara Plaimauer

Helena Elisabeth Schaller-Gerritsen

Markus Fries

Koenraad Mertens

Falko-Günter Falkner

Falko Gunter Falkner

Manfred Rieger

Zhihao Fang

Mary J Bossard

Ping Zhang

Katalin Varadi

Eberhard Schneider

Ulf Reimer

Herbert Gritsch

Gayle Stephenson

Harold Zappe

Hans Pannekoek

Stacy Mitchell

Dirk Voelkel

Jan Aart Van Mourik

Michael Thiele

Petrus Johannes Lenting

Ernst Boehm

Falko-Guenter Falkner

Geert Mudde

Denisa D Wagner

Bruce Ewenstein

Matthias Paschke

Michael Pfleiderer

Patrice Douillard

Olaf Merkel

Michele Himmelspach

Bettina Hartlieb

Michel Canavaggio

Anil Kumar Chauhan

Susanne Till

Sabine Knappe

Rene Hoet

Hans Christian Hedrich

Klaus Tschetschkowitsch

Falko-Gunter Falkner

Andreas Goppelt

Alexander Schinagl

Brahm Goldstein

Bernhard Majer

Paolo Rossato

Marietta Turecek

Zhenqing Zhang

Christina Szabo

Helena Elisabeth Gerritsen

Jan Voorberg

Arend N Bovenschen

Juergen Muellberg

Jueren Siekmann

Tobias M Suiter

Wing Yen Wong

Petra Boeck-Taferner

C Geert Mudde

Jürgen Muellberg

Denisa Wagner

Arend Niels Bovenschen

Bernadette Gruber

Silvia Ferrari

Peter Leopold Turecek

Randolf J Kerschbaumer

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.

TFPI inhibitors and methods of use

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.

Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia B. In some embodiments, the present disclosure provides methods for dosing a hemophilia B patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor IX polypeptide.

Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression

The present invention pertains to the specific detection of MIF, in particular oxMIF, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anti-oxMIF antibodies are used.

Anti-MIF immunohistochemistry

The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.

Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA&#xae;, but require a lower concentration of FII are described herein.

Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.

ADAMTS13-containing compositions having thrombolytic activity

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

Codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells are provided, including sequences with high nucleotide sequence identity to the CS02, CS03, CS04, CS05, and CS06 sequences. Mammalian gene therapy vectors, such as adeno-associated viral vectors, and methods for treating hemophilia B using those vectors are also provided.

Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B

A peptide or peptide derivative comprising: A peptide or peptide derivative comprising:

Biologically active peptides

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.

The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.

Factor VIIa-polysialic acid conjugates having prolonged in vivo half-life

Growing community of inventors

Vienna, Austria

Friedrich Scheiflinger